Is REGENERON PHARMACEUTICALS, INC. (REGN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 3.4% / 30% | 10.7% / 30% | 7.1% / 30% | 5.0% / 5% | ✓ HALAL |
| DJIM | 3.4% / 33% | 10.7% / 33% | 7.1% / 33% | 5.0% / 5% | ✓ HALAL |
| MSCI | 6.7% / 33% | 21.2% / 33% | 14.2% / 33% | 5.0% / 5% | ✓ HALAL |
| S&P | 3.4% / 33% | 10.7% / 33% | 7.1% / 33% | 5.0% / 5% | ✓ HALAL |
| FTSE | 6.7% / 33% | 21.2% / 33% | 14.2% / 50% | 5.0% / 5% | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 44.6% | |
| Operating Margin | 23.1% | |
| Net Margin | 31.4% | |
| Return on Equity (ROE) | 14.9% | |
| Return on Assets (ROA) | 5.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $5.0B |
| Free Cash Flow | $3.8B |
| Total Debt | $2.7B |
| Debt-to-Equity | 9.5 |
| Current Ratio | 4.1 |
| Total Assets | $40.6B |
Price & Trading
| Last Close | $756.73 |
| 50-Day MA | $763.44 |
| 200-Day MA | $657.88 |
| Avg Volume | 747K |
| Beta | 0.4 |
|
52-Week Range
$476.49
| |
About REGENERON PHARMACEUTICALS, INC. (REGN)
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company was incorporated in 1988 and is based in Tarrytown, New York.
Purification Calculator
As a halal stock with 5.00% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is REGENERON PHARMACEUTICALS, INC. (REGN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), REGENERON PHARMACEUTICALS, INC. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is REGENERON PHARMACEUTICALS, INC.'s debt ratio?
REGENERON PHARMACEUTICALS, INC.'s debt ratio is 3.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 6.7%.
Does REGENERON PHARMACEUTICALS, INC. require dividend purification?
Yes, REGENERON PHARMACEUTICALS, INC. has an impermissible income ratio of 5.00%, which means 5.00% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are REGENERON PHARMACEUTICALS, INC.'s key financial metrics?
REGENERON PHARMACEUTICALS, INC. has a market capitalization of $78.0B, trailing P/E ratio of 17.8, and revenue of $14.3B. The company maintains a gross margin of 44.6% and a net margin of 31.4%. Return on equity stands at 14.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.